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Background: Overweight subjects easily develop alterations of the glucose and lipid metabolism and are exposed
to an increased cardiometabolic risk. This condition is potentially reversible through the improvement of dietary
and behavioural habits. However, a well-assembled nutraceutical would be a useful tool to better improve the
metabolic parameters associated to overweight and insulin resistance.
Methods: To evaluate the effect of a combined nutraceutical containing berberine, chlorogenic acid and
tocotrienols, we performed a double blind, cross-over designed trial versus placebo, in 40 overweight subjects
with mixed hyperlipidaemia. After the first 8 weeks of treatment (or placebo), patients were asked to observe a
2-week washout period, and they were then assigned to the alternative treatment for a further period of 8 weeks.
Clinical and laboratory data associated to hyperlipidaemia and insulin resistance have been obtained at the
baseline, at the end of the first treatment period, after the washout, and again after the second treatment period.
Results: Both groups experienced a significant improvement of anthropometric and biochemical parameters
versus baseline. However, total cholesterol, LDL cholesterol, triglycerides, non-HDL cholesterol, fasting insulin,
HOMA-IR, GOT and Lipid Accumulation Product decreased more significantly in the nutraceutical group versus
placebo.
Conclusions: This combination seems to improve a large number of metabolic and liver parameters on the
short-term in overweight subjects. Further studies are needed to confirm these observations on the middle- and
long-term.
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Overweight and obesity are a worldwide leading health
problem [1], especially when complicated by other dis-
eases [2]. In particular, overweight is usually associated
to a large number of metabolic changes, such as reduc-
tion of insulin-sensitivity, dyslipidaemia, accumulation of
lipids in the liver, respectively predisposing to the* Correspondence: afgcicero@cardionet.it
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unless otherwise stated.development of type 2 diabetes, atherosclerosis and non-
alcoholic steatohepatitis, all conditions increasing the
risk to develop cardiovascular disease [3,4]. All these
changes are potentially reversible with intensification of
physical activity and improvement of dietary habits [5],
while the efficacy/safety ratio of the available pharma-
ceutical drugs is not yet adequately defined [6].
Recent literature shows that a number of natural com-
pounds seem to have positive effects on the metabolic
changes associated to overweight [7,8]. Of particular
interest seems to be soluble fibres, cinnamon, chromiumThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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genic acid, green tea, bitter gourd and banaba.
The main limitation in the clinical use of these products
are the need to assume large quantities (for instance, cin-
namon and bitter gourd), the scarce availability of clinical
data (for instance, banaba), the relatively small metabolic
effect (for instance, fibres and chromium), the need to use
low doses in order to avoid side effects (for instance, ber-
berine), and the cost (for instance, high quality green tea)
[9]. On the other side, scarce data are available as it regards
the clinical efficacy of combination of these substances.
In this context, the aim of our study was to evaluate
the short-term metabolic effects of a combined nutra-
ceutical containing berberine and chlorogenic acid on
overweight subjects with mixed hyperlipidemia.
Methods and materials
Study design
This double blind, placebo controlled, randomized clin-
ical trial was carried out in 40 moderately hypercholes-
terolemic subjects with metabolic syndrome, in primary
prevention for cardiovascular diseases, consecutively en-
rolled in the ambulatory service of cardiovascular disease
prevention in the Medical and Surgical Sciences Depart-
ment of the University of Bologna.
The study consisted in a cross-over designed trial of
18 weeks, preceded by 4 weeks of diet stabilization in
which patients received standard behavioural and quali-
tative (not quantitative) dietary suggestions to correct
unhealthy habits. In particular, subjects were instructed
to follow a general indication of a Mediterranean diet,
avoiding excessive intake of dairy products and red meat
derived products during the study, and maintaining
overall constant dietary habits. Individuals were also
generically encouraged to increase their physical activity
by walking briskly for 20 to 30 minutes, 3 to 5 times per
week, or by cycling.
Inclusion criteria were:
– age between 25 and 75
– LDL-Cholesterol (LDL-C) level between 130 and
190 mg/dl
– Body Mass Index (BMI) value between 25 and
30 kg/m2
– Triglycerides (TG) level between 150 and 400 mg/dl
– Fasting Plasma Glucose (FPG) level under 125 mg/dl.
– When present, assumption of hypolipidaemic or
antihypertensive drugs stabilized since at least
6 months.
Exclusion criteria were:
– secondary prevention for cardiovascular diseases
– assumption of antidiabetic drugs– inconstant or not-stabilized assumption of drugs
which may interfere with lipid or glucose
metabolism
– chronic gastrointestinal diseases and assumption of
drugs for their treatment
– known thyroid, liver, renal or muscle diseases
– known allergy or intolerance to a component of the
tested product
– any medical or surgical condition which could lead
to an inconstant adhesion to the protocol.
The study was fully conducted in accordance with the
Declaration of Helsinki, its protocol was approved by
the Ethical Committee of the University of Bologna, and
informed consent was obtained from all patients before
the inclusion in the study.
Treatments
After 4 weeks of diet and physical activity stabilization,
patients were allocated to treatment with an indistin-
guishable pill of placebo or with an active product
(Trixy®) containing Berberine from Berberis aristata,
Tocotrienols form Elaeis guineensis and Chlorogenic
acid form decaffeinated Green coffee (Coffea canephora),
kindly offered by Nathura s.r.l. (Montecchio Emilia, RE).
After 8 weeks of treatment (or placebo), patients were
asked to observe a 2-week wash-out period, and they
were then assigned to the alternative treatment for a fur-
ther period of 8 weeks. Clinical and laboratory data have
been obtained at the baseline, at the end of the first
treatment period, after the wash-out, and again after the
second treatment period.
Randomization was done assigning an alphabetical
code to each lot code (corresponding to treatment or
placebo) impressed on the pillbox. Codes were then kept
in a sealed envelope which was not opened until the end
of the trial. Pillboxes were then mixed, and the investiga-
tors assigned a blinded pillbox to each enrolled patient.
Throughout the study, we instructed patients to take
the product first dose on the day after they were given
the study product. At the same time, all unused products
were retrieved to the investigator.
Assessments
Personal data, CVD history and pharmaceutical anamnesis
of each patient were inquired at the beginning of the trial.
Anthropometrical parameters, such as body weight, waist
circumference and BMI were collected both at the begin-
ning and during the trial, together with hemodynamic and
biochemical parameters. BMI was calculated as weight in
kilograms divided by the square of height in meters.
Hemodynamic parameters were collected measuring ortho-
static and clinostatic systolic and diastolic blood pressure
(mean value of 3 interval measures). Also orthostatic and
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measures) and cardiac frequency were collected.
All biochemical parameters were obtained after a 12-
hour overnight fast. The following parameters were ob-
tained or calculated through appropriate formulas: total
cholesterol (TC) [10], high-density lipoprotein-cholesterol
(HDL-C) [11], TG [12], LDL-C [13], non-HDL cholesterol
(nonHDL-C), lipoprotein(a) (Lpa), FPG, fasting insulin,
homeostatic model assessment of insulin resistance
(HOMA-IR) [14], creatinine, Serum Uric Acid (SUA),
liver transaminases (glutamic oxaloacetic transaminase,
GOT; glutamate-pyruvate transaminase, GPT), Gamma
Glutamyl-Transferase (γGT), Lipid Accumulation Prod-
uct (LAP) and Hepatic Steatosis Index (HSI) [15]. All
measurements were centrally performed in the labora-
tory of our department.
HOMA-IR is the simplest and most commonly used
method to estimate insulin resistance. It was calculated
as the product of basal glucose (mmol/l) and fasting in-
sulin (μU/ml) divided by 22.5 [14].
LAP is calculated through the following formulas: (waist
circumference (cm) - 65) × (TG (mmol/l)) for men and:
(waist circumference (cm) - 58) × (TG (mmol/l)) for
women, and is a useful marker of the individual cardiomet-
abolic risk [16]. HSI, instead, is a simple index used to
evaluate the presence or the severity of Non-alcoholic Fatty
Liver Disease (NAFLD) through some biochemical parame-
ters (TG, BMI, yGT, waist circumference) [16]. Adherence
to behavioural counselling and to treatment/placebo, toler-
ability, acceptability and compliance were also assessed.
Statistical analyses
The main outcome of the study was to evaluate the dif-
ferent effect of the active treatment and placebo onTable 1 Baseline characteristics of the subjects enrolled in th
N. 40 Mean SD
Age (years) 53.45 8.00
Weight (kg) 82.00 11.45
Body Mass Index (kg/m2) 28.75 2.65
Waist Circumference (cm) 106.30 10.85
SBP (mmHg) 135.50 14.90
DBP (mmHg) 80.60 7.30
Pulse Pressure (mmHg) 54.90 12.10
MAP (mmHg) 98.95 8.75
Heart Rate (bpm) 73.80 5.60
FPG (mg/dL) 106.90 6.70
Insulin (μU/ml) 14.50 4.30
HOMA-IR 4.05 1.20
Acronyms: SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean a
non HDL cholesterol, FPG: fasting plasma glucose, HOMA-IR: homeostatic model ass
GPT: glutamate-pyruvate transaminase, LAP: lipid accumulation product, HSI: hepatiHOMA-index. Thus, we calculated the sample size of
the study on the assumption that the HOMA-index
standard deviation of the difference in the response vari-
ables is 0.7, so that with 40 patients enrolled, the prob-
ability was 80 percent that the study would have
detected a treatment difference at a two-sided 0.05 sig-
nificance level, if the true difference between treatments
is 0.318 units.
Data have been analysed using intention to treat by
mean of the Statistical Package for Social Science (SPSS)
21.0, version for Windows. Normally distributed baseline
characteristics of the population have been compared
using Student’s t test, non-normally distributed parame-
ters using Mann–Whitney-U test. Two-way analyses of
variance for crossover design were used to assess the ef-
fect of treatment during the assumption of placebo or
treatment. All data are expressed as means and Standard
Deviation (SD). To verify the basic assumptions of cross-
over design, besides the evaluation of period effect, the
presence of a carryover effect was excluded. Level of
statistical significance was set on P = 0.05.
Results
The main characteristics of the enrolled patients have
been resumed in Table 1. At the baseline the two treat-
ment sequence group were balanced for all the investi-
gated parameters. All the patients completed the study
and no one experienced adverse events during the trial.
Compared to baseline values, no change has been ob-
served after both treatments as it regards Diastolic Blood
Pressure (DBP), Pulse Pressure (PP), Heart Rate (HR),
GOT, HSI, creatinine and SUA level.
Both groups experienced a significant decrease in body
weight, BMI and waist circumference (p < 0.001), withoute trial
Mean SD
Total Cholesterol (mg/dL) 215.70 15.20
LDL-C (mg/dL) 132.15 17.50
Triglycerides (mg/dL) 222.05 38.70
HDL-C (mg/dL) 39.10 3.40
Non HDL-C (mg/dL) 176.60 15.40
GOT (U/L) 24.90 10.10
GPT (U/L) 28.10 12.95
Serum Uric Acid (mg/dL) 4.50 1.30
Creatinine (mg/dL) 8.95 1.25
LAP 111.40 34.35
HSI 37.05 3.60
rterial pressure, LDL-C: LDL cholesterol, HDL-C: HDL cholesterol, Non HDL-C:
essment of insulin resistance, GOT: glutamic oxaloacetic transaminase,
c steatosis index.
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mean arterial pressure mildly, but significantly improved
after diet-nutraceutical treatment. Lipid pattern improved
after both treatments, however after diet-nutraceutical
treatment TC, LDL-C, TG, and non-HDL-C decreased
more significantly than after diet alone (p < 0.001). After
diet-nutraceutical treatment HDL-C also mildly, but sig-
nificantly, increased versus baseline. FPG similarly de-
creased after both treatments, but fasting insulin and
HOMA significantly decreased versus baseline values after
diet-nutraceutical treatment only: the reduction was also
significant versus diet-placebo (p < 0.001 for both HOMA-
IR and insulin). Then, GOT improved versus baseline and
versus diet-placebo (p < 0.001) after diet- nutraceutical
treatment. Finally, LAP improved after both treatments,
but the reduction after diet-nutraceutical treatment was
significantly higher than the one obtained with diet-
placebo (p = 0.021) (Table 2).
The wash-out did not determine a significant carry-
over effect in both group, probably because its relatively
short duration and because the improvement in dietary
habits persisted during this phase. However, the groupTable 2 Mean difference in changes of the studied parameter
N.40 Mean difference
in changes
Δ Weight (kg) −0,2
Δ Body Mass Index (kg/m2) −0,1
Δ Waist Circumference (cm) −0,6
Δ Systolic Blood Pressure (mmHg) 0,2
Δ Diastolic Blood Pressure (mmHg) 0,8
Δ Pulse Pressure (mmHg) −0,5
Δ Mean Arterial Pressure (mmHg) 0,5
Δ Heart Rate (bpm) −0,1
Δ Total Cholesterol (mg/dL) −19,5
Δ LDL-C (mg/dL) −15,4
Δ Triglycerides (mg/dL) −21,4
Δ HDL-C (mg/dL) 0,3
Δ Non HDL-C (mg/dL) −19,7
Δ Fasting Plasma Glucose (mg/dL) −0,1
Δ Insulin (μU/ml) −1
Δ HOMA-IR −0,3
Δ GOT (U/L) −0,3
Δ GPT (U/L) −7,8
Δ Serum Uric Acid (mg/dL) −2,4
Δ Creatinine (mg/dL) −0,5
Δ Lipid Accumulation Product −10,4
Δ Hepatic Steatosis Index 1,3
Acronyms: LDL-C: LDL cholesterol, HDL-C: HDL cholesterol, Non HDL-C: non HDL ch
glutamic oxaloacetic transaminase, GPT: glutamate-pyruvate transaminase.who began with diet-nutraceutical treatment, at the end
of the study experience a regression of a large number
of metabolic parameters (HOMA-index, TC, LDL-C,
non HDL-C) to values no more significantly different
than the baseline ones (p > 0.05 for all).Discussion
The insulin-sensitizing property of coffee [15] has been
partly attributed to its content in chlorogenic acid, an
ester formed from cinnamic acids and quinic acid. In par-
ticular, chlorogenic acid seems to act as insulin sensitizer
that potentiates insulin action similar to the therapeutic
action of metformin [17]. However, recent data suggest
that it could also exert its antidiabetic action by inhibiting
α-amylase and α-glucosidase activities [18].
Moreover, the effect of chlorogenic acid on expression
of hepatic peroxisome proliferator-activated receptor-
alpha [19] and on activation of 5′ AMP-activated protein
kinase [20] partly explain the presumed liver protective
effect of coffee from non-alcoholic fatty liver disease
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both inhibiting the liver LDL-receptor inactivation by
inhibiting PCSK9 and activating the 5′ AMP-activated
protein kinase [22]. Moreover, berberine exerts insulin-
sensitizing effects with a metformin-like mechanism of
action [23]. Recent data also suggest that berberine
could also induce improvement in liver steatosis, prob-
ably as consequence of the relevant changes induced in
triglycerides level and insulin-sensitivity [24].
So, as expected from the available literature data (16–
24), after a combined treatment with berberine and
chlorogenic acid we observed a significant improvement
in LDL-C (−24%), TG (−19%), non HDL-C (−22%), fast-
ing insulin (−5%) and HOMA index (−10%). Moreover,
we also observed a significant improvement in LAP
(−25%), a validated index of liver steatosis [16].
All these effects could be particularly relevant in the
management of overweight subjects complicated with
metabolic syndrome and/or non-alcoholic fatty liver dis-
ease, both condition associated to high cardiometabolic
disease risk [25,26] and whose management is actually
mainly based on diet and life-style improvement [27,28].
This study has some limitation. The first one is the
relatively small sample size, partially balanced by the
cross-over design of the trial. The second one is the rela-
tively short duration of the trial, however comparable
with the most part of explorative trials carried out with
metabolically active nutraceuticals. Then, we have not
prescribed a specific diet based on bromatological data,
but we gave only general dietary suggestion finalized at
avoiding dietary excess in order to simulate more strictly a
condition of general practice. Finally, we have not directly
evaluated the degree of liver steatosis. On the other side,
validated index of liver steatosis have been used, sup-
ported by recent literature. Finally, we did not compare
the effects of berberine and chlorogenic acid alone and
with their association, but the effect of the two compo-
nents alone on the parameters investigated was already
known in literature.
Conclusions
On the basis of our preliminary data, a nutraceutical
containing berberine and chlorogenic acid seems to be
well-tolerated and able to improve a large number of
metabolic and liver parameters on the short-term in
overweight patients with mixed hyperlipidaemia. Further
studies are needed to confirm these observations on the
middle- and long-term.
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